Skip Navigation LinksHome > May 2013 - Volume 19 - Issue 6 > Risk Factors for Osteoporosis in Crohn's Disease: Infliximab...
Inflammatory Bowel Diseases:
doi: 10.1097/MIB.0b013e31828075a7
Original Clinical Article

Risk Factors for Osteoporosis in Crohn's Disease: Infliximab, Corticosteroids, Body Mass Index, and Age of Onset

Azzopardi, Neville MD; Ellul, Pierre MD

Collapse Box

Abstract

Background:

We analyzed the characteristics associated with increased risk of osteoporosis in patients with Crohn's disease in Malta.

Method:

Eighty-three patients with histologically and endoscopically confirmed Crohn's disease underwent a DEXA bone density scan and their phenotypic characteristics were analyzed.

Results:

There was a significant association between body mass index and bone mineral density (P = 0.004) and a significant difference in the T scores of patients according to age at diagnosis (Montreal Classification: P = 0.0006) with patients diagnosed <17 years (n = 13) having lower T scores than those diagnosed at older age groups (n = 70). There was a significant difference between the T scores of patients on infliximab (n = 33) and those not on biological therapy (n = 50, P = 0.0058). Patients with high cumulative corticosteroid doses (>10 mg/d for >3 mo, n = 18) had lower bone mineral densities than patients who received smaller corticosteroid doses (P = 0.013). There was however no significant difference in the T scores of patients according to disease location (P = 0.18), disease type (P = 0.64), gender (P = 0.30), and history of ileal resection (P = 0.68). There was also no significant correlation between disease duration and T scores (hip) (P = 0.61).

Conclusions:

Low body mass index, early disease onset, high corticosteroid doses and, anti–tumor necrosis factor α therapy are associated with increased risk of osteoporosis. Lower T scores in patients on infliximab occur as patients receiving this therapy have more severe inflammation, which is associated with elevated osteoclastogenic factors, rather than as a side-effect of the anti–tumor necrosis factor-α therapy.

Copyright © 2013 Crohn's & Colitis Foundation of America, Inc.

You currently do not have access to this article.

You may need to:

Note: If your society membership provides for full-access to this article, you may need to login on your society’s web site first.

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.